银诺医药-B(02591)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02591 银诺医药-B

未开盘 05-19 16:08:19

14.340

+2.300

+19.10%

最高18.910	最低12.160	成交量4,694万
今开12.380	昨收12.040	日振幅56.06%
总市值65.53亿	流通市值60.27亿	总股本4.57亿
成交额7.24亿	换手率11.17%	流通股本4.20亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02591","market":"HK","secType":"STK","nameCN":"银诺医药-B","latestPrice":14.34,"timestamp":1779178099066,"preClose":12.04,"halted":0,"volume":46944800,"delay":0,"changeRate":0.191029900332226,"floatShares":420285370,"shares":457000000,"eps":-0.9077880736603822,"marketStatus":"未开盘","change":2.3,"latestTime":"05-19 16:08:19","open":12.38,"high":18.91,"low":12.16,"amount":724208011,"amplitude":0.560631,"askPrice":14.34,"askSize":115400,"bidPrice":14.27,"bidSize":11000,"shortable":0,"etf":0,"ttmEps":-0.9503047302748557,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1779240600000},"marketStatusCode":0,"adr":0,"listingDate":1755187200000,"exchange":"SEHK","adjPreClose":12.04,"openAndCloseTimeList":[[1779154200000,1779163200000],[1779166800000,1779177600000]],"volumeRatio":10.18732,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02591","defaultTab":"news","newsList":[{"id":"2635771239","title":"港股午评|恒生指数早盘跌0.87%      机器人板块逆市大涨","url":"https://stock-news.laohu8.com/highlight/detail?id=2635771239","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635771239?lang=zh_cn&edition=full","pubTime":"2026-05-15 12:00","pubTimestamp":1778817625,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，港股恒生指数跌0.87%，跌229点，报26159点；恒生科技指数跌1.26%。港股早盘成交1511亿港元。机器人产业进入量产博弈阶段。均胜电子涨6%，公司聚焦机器人核心部件以及相关总成方案。通用Token降价引爆市场需求，迅策垂类Token溢价及需求坚挺。阿里健康跌超6%，年度经调整净利同增19.3%，公司CFO发生变更。建滔积层板跌4.87%，中国巨石宣布扩产，花旗料短期或对公司造成负面市场情绪。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1442090.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["600362","BK1116","03317","06127","513600","BK4588","02833","003021","01208","600699","02692","02591","00358","HHImain","603127","603986","01888","BK4585","MCHmain","02432","01801","002747","02715","03986","00699","HSI","00241","BK1183","HSTECH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1151835241","title":"异动解读 | 银诺医药-B盘中大跌近6%，股价逼近历史前低，基石投资者股份今日解禁及业绩亏损扩大拖累股价","url":"https://stock-news.laohu8.com/highlight/detail?id=1151835241","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1151835241?lang=zh_cn&edition=full","pubTime":"2026-05-15 11:05","pubTimestamp":1778814327,"startTime":"0","endTime":"0","summary":"银诺医药-B今日盘中大跌5.93%，股价逼近历史前低，引发市场关注。消息面上，根据公司此前公告，基石投资者的禁售期已于昨日届满，相关股份于今日正式解禁流通，合计持股420.1万股。市场担忧解禁后可能出现的抛售压力，对股价构成直接冲击。此外，公司2025年度业绩显示，期内净亏损达3.41亿元，同比大幅扩大95.4%，基本面疲软进一步削弱了投资者信心。尽管有分析指出，其核心产品Suba的III期减重数据预计于2026年年底前公布，但短期内，股份解禁带来的供给增加与不佳的财务表现共同主导了此次股价下跌。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02591"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1192588250","title":"异动解读 | 银诺医药-B盘中大跌5.46%，基石投资者禁售期届满与亏损扩大引发担忧","url":"https://stock-news.laohu8.com/highlight/detail?id=1192588250","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1192588250?lang=zh_cn&edition=full","pubTime":"2026-05-14 14:19","pubTimestamp":1778739592,"startTime":"0","endTime":"0","summary":"银诺医药-B(02591)今日盘中股价出现大幅下跌，跌幅达5.46%。消息面上，公司基石投资者的禁售期即将届满，相关股份将于近期正式解禁流通，涉及约420.1万股，市场担忧这可能带来额外的抛售压力。此外，公司公布的2025年度业绩显示，净亏损同比扩大95.41%至3.41亿元人民币，同时研发开支大幅增加，财务状况引发投资者关注。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02591"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635760237","title":"港股异动 | 银诺医药-B(02591)再跌超5% 基石投资者禁售期即将届满","url":"https://stock-news.laohu8.com/highlight/detail?id=2635760237","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635760237?lang=zh_cn&edition=full","pubTime":"2026-05-14 14:13","pubTimestamp":1778739235,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，银诺医药-B(02591)再跌超5%，该股本周一曾放量大涨超32%，此后三天连续回落。截至发稿，跌5.32%，报13.7港元，成交额2169.17万港元。消息面上，据银诺医药此前公告，基石投资者的禁售期将于2026年5月14日届满，相关股份将于5月15日正式解禁流通。其中，基石投资者合计持股420.1万股。财务方面来看，银诺医药2025年度业绩显示显示，公司期内取得营业收入1.32亿元人民币，主要来自于在中国销售依苏帕格鲁肽α。净亏损3.41亿元 ，亏损同比扩大95.41%。期内研发开支翻倍至2.06亿元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1441629.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK4585","VXUS","02591","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634229513","title":"港股异动 | 银诺医药-B(02591)跌逾9% 昨日收涨超32% 基石投资者本周将迎来解禁","url":"https://stock-news.laohu8.com/highlight/detail?id=2634229513","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634229513?lang=zh_cn&edition=full","pubTime":"2026-05-12 15:48","pubTimestamp":1778572101,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，银诺医药-B跌逾9%，昨日曾收涨超32%。截至发稿，跌9.1%，报15.18港元，成交额1.31亿港元。消息面上，据银诺医药此前公告，基石投资者的禁售期将于2026年5月14日届满，相关股份将于5月15日正式解禁流通。其中，基石投资者合计持股420.1万股。银诺医药2025年度业绩显示，期内集团产生约1.315亿元的收入，主要来自于在中国销售依苏帕格鲁肽α。净亏损3.41亿元，同比扩大95.4%。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1440649.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK4588","VXUS","BK4585","02591","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188980056","title":"港股部分生物医药股走强！银诺医药-B涨超42%，三叶草生物-B涨超11%","url":"https://stock-news.laohu8.com/highlight/detail?id=1188980056","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1188980056?lang=zh_cn&edition=full","pubTime":"2026-05-11 13:25","pubTimestamp":1778477154,"startTime":"0","endTime":"0","summary":"5月11日，港股部分生物医药股走强，$银诺医药-B(02591)$涨超42%，$三叶草生物-B(02197)$涨超11%，$君实生物(01877)$涨超8%，$来凯医药-B(02105)$涨超7%，$荃信生物-B(02509)$涨近5%，$药明巨诺-B(02126)$涨超3%。","market":"hk","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"68e9cc22a457e84dfc55ae6520639fb8","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["161726","VXUS","BK1161","02591","02197","399441","BK4581","BK4585","XBI","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634476449","title":"港股异动 | 银诺医药-B(02591)午前涨超43% Suba的III期减重数据预计2026年年底前公布","url":"https://stock-news.laohu8.com/highlight/detail?id=2634476449","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634476449?lang=zh_cn&edition=full","pubTime":"2026-05-11 11:37","pubTimestamp":1778470647,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，银诺医药-B午前涨超43%，截至发稿，涨42.21%，报17.99港元，成交额1.73亿港元。消息面上，银诺医药年度业绩显示，2025 年实现收入1.32亿元，亏损3.41亿元。值得注意的是，银诺医药基石投资者的禁售期将于2026年5月14日届满，相关股份将于5月15日正式解禁流通。Suba的III期减重数据预计2026年年底前公布。治疗肥胖及超重的III期临床研究，已于2025年完成患者入组。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"68e9cc22a457e84dfc55ae6520639fb8","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1440054.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02591","III","VXUS","BK4588","BK4585","BK1161","BK4134"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633194089","title":"港股异动 | 银诺医药-B(02591)午后跌超7% 股价创上市新低 基石投资者的禁售期将于5月14日届满","url":"https://stock-news.laohu8.com/highlight/detail?id=2633194089","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633194089?lang=zh_cn&edition=full","pubTime":"2026-05-07 14:12","pubTimestamp":1778134360,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，银诺医药-B(02591)午后跌超7%，低见12.33港元，创上市新低，截至发稿，跌6.16%，报12.49港元，成交额1102.07万港元。消息面上，银诺医药年度业绩显示，营业收入1.32亿元人民币，净亏损3.41亿元 ，亏损同比扩大95.41%。期内研发开支翻倍至2.06亿元。值得注意的是，银诺医药基石投资者的禁售期将于2026年5月14日届满，相关股份将于5月15日正式解禁流通。其中，基石投资者合计持股420.1万股。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1438958.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["VXUS","BK4588","02591","BK1161","BK4585","IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1113071515","title":"银诺医药-B 4月股本维持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1113071515","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1113071515?lang=zh_cn&edition=full","pubTime":"2026-05-06 10:46","pubTimestamp":1778035569,"startTime":"0","endTime":"0","summary":"广州银诺医药集团股份有限公司于2026年5月6日发布的截至2026年4月30日的证券变动月报表显示，公司报告期内未发生股份发行、购回或库存股份变动，股本维持稳定。根据公告披露，截至2026年4月30日，公司法定/注册股本合计为人民币456,819,349元，与上月末持平。本次公告由联席公司秘书杨东妍签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02591"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1151720253","title":"银诺医药-B首度实现1.32亿元商业收入，深耕代谢性疾病创新药物与全球化布局","url":"https://stock-news.laohu8.com/highlight/detail?id=1151720253","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1151720253?lang=zh_cn&edition=full","pubTime":"2026-04-28 22:56","pubTimestamp":1777388184,"startTime":"0","endTime":"0","summary":"截至2025年12月31日止年度，银诺医药-B在研发布局与商业化推进取得阶段性成效，首次实现收入约1.32亿元人民币，主要来自代谢性疾病创新药物在中国内地及部分境外地区的销售。本年度研发开支达2.06亿元人民币，较上一年度有显著提升，主要投入于以GLP-1类药物为代表的核心管线，以及肥胖、MASH等多适应症的临床研究。受研发及市场推广投入增加影响，公司年内亏损扩大至3.41亿元人民币。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"银诺医药-B首度实现1.32亿元商业收入，深耕代谢性疾病创新药物与全球化布局","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02591"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629815491","title":"首款国产长效GLP-1年销破亿，却陷“卖得越多亏得越深”困局：银诺医药的三大结构性风险","url":"https://stock-news.laohu8.com/highlight/detail?id=2629815491","media":"新浪证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629815491?lang=zh_cn&edition=full","pubTime":"2026-04-24 16:02","pubTimestamp":1777017720,"startTime":"0","endTime":"0","summary":"2025年，随着依苏帕格鲁肽α注射液获批上市，银诺医药成为国产长效GLP-1赛道“第一个吃螃蟹的人”。一年后，公司交出了首份含规模化营收的财报：1.32亿元营收、89%的毛利率、3.41亿元净亏损。　　资本市场曾对国产GLP-1寄予厚望，但这组数据却揭示了一个更为冷峻的现实：产品上市并不等于商业成功。在跨国巨头与仿制药大军双重夹击下，银诺医药正面临三大结构性风险。　　2025年，银诺医药的毛利率高达89%，这一数字在创新药企中可谓亮眼。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/aigcy/2026-04-24/doc-inhvqwcw4356487.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4590","GLP","BK1161","BK4144","02591"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628758465","title":"卖得越多亏得越多！银诺医药长效GLP-1首年收入1.32亿元，净亏损为何反升至3.41亿元？｜财报异动透视镜","url":"https://stock-news.laohu8.com/highlight/detail?id=2628758465","media":"华夏时报网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628758465?lang=zh_cn&edition=full","pubTime":"2026-04-18 21:14","pubTimestamp":1776518099,"startTime":"0","endTime":"0","summary":"营收1.32亿元、毛利率89%、净亏损同比扩大95.4%，国产长效GLP-1的故事该怎么讲？近日，首款国产长效GLP-1的母公司银诺医药发布2025年财报，备受业内关注。其净亏扩大至3.41亿元，同比激增95.4%。据悉，上述营收全部来自依苏帕格鲁肽α的销售。这意味着，国产长效GLP-1首年销售额破亿元的光环下，银诺医药深陷“卖药越多，亏损越多”的经营困境。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604183709758353.html","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604183709758353.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["02591","GLP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626971244","title":"港股医药股延续涨势 银诺医药涨近9%","url":"https://stock-news.laohu8.com/highlight/detail?id=2626971244","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626971244?lang=zh_cn&edition=full","pubTime":"2026-04-09 09:44","pubTimestamp":1775699058,"startTime":"0","endTime":"0","summary":"每经AI快讯，4月9日，港股医药股延续涨势。截至发稿，银诺医药-B(02591.HK)涨8.70%，百赛图奥-B(02315.HK)涨5.86%，昭衍新药(06127.HK)涨4.90%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604093699184792.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604093699184792.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["02591","BK1161","159718"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1138442324","title":"银诺医药-B更新3月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1138442324","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1138442324?lang=zh_cn&edition=full","pubTime":"2026-04-08 18:36","pubTimestamp":1775644562,"startTime":"0","endTime":"0","summary":"2026年4月8日，银诺医药-B公布截至2026年3月31日的股份变动月报表。报告显示，公司本月未有新增发行股份或购回活动，股本结构与前月相比保持不变。\n根据公告，公司注册股本总额为人民币456,819,349元，包含420,285,370股于香港联交所上市的H股及36,533,979股非上市股份。报告期内，已发行股份及库藏股份数量均无变化，H股和非上市股份数分别维持在420,285,370股和36,533,979股。\n公告进一步说明，当月无股份期权、可换股票据或其他发行业务方面的变动，截至3月末，公司股本总数保持稳定，继续满足香港联交所的公众持股量要求。该月报表由联席公司秘书杨东妍签署。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02591"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625679421","title":"银诺医药-B（02591）：2025年亏损扩大近1倍，转型阵痛下股价腰折超7成","url":"https://stock-news.laohu8.com/highlight/detail?id=2625679421","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625679421?lang=zh_cn&edition=full","pubTime":"2026-04-06 20:03","pubTimestamp":1775477036,"startTime":"0","endTime":"0","summary":"2025年对银诺医药-B而言是战略转型的关键一年，公司从专注研发的公司转型为研发与商业化并行的公司。受益于依苏帕格鲁肽α商业化落地，银诺医药2025年首度实现规模化营收，全年实现收入约1.32亿元。截至2026年4月2日收盘，公司股价报20.86港元，年内跌幅达31.92%，市场信心仍需进一步修复。2025年基本每股亏损0.79元，较2024年的0.42元明显扩大，核心原因在于研发与销售的高强度投入，显著超出了当期收入水平。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1425296.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"银诺医药-B（02591）：2025年亏损扩大近1倍，转型阵痛下股价腰折超7成","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02591"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624212503","title":"首个国产长效GLP-1产品成绩单出炉，银诺医药一年亏3.4亿，GLP-1价格战已经打响","url":"https://stock-news.laohu8.com/highlight/detail?id=2624212503","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624212503?lang=zh_cn&edition=full","pubTime":"2026-04-02 19:11","pubTimestamp":1775128291,"startTime":"0","endTime":"0","summary":"可以预见，随着大量仿制药涌入，GLP-1的价格将面临进一步巨大冲击，而GLP-1价格战已经悄然打响。2025年6月，玛仕度肽获NMPA批准用于肥胖或超重成人的慢性体重管理。在国内，目前还没有专门为“减肥”适应症获批上市的口服GLP-1药物。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1775118515212957683","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["BK1161","BK4590","BK4144","GLP","02591"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624567526","title":"港股异动 | 银诺医药-B(02591)早盘涨超3% 依苏帕格鲁肽α正式纳入“齐鲁保”特定药品清单","url":"https://stock-news.laohu8.com/highlight/detail?id=2624567526","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624567526?lang=zh_cn&edition=full","pubTime":"2026-04-02 09:33","pubTimestamp":1775093582,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，银诺医药-B早盘涨超3%，截至发稿，涨2.94%，报22.22港元，成交额196.6万港元。消息面上，4月1日，据银诺医药官微消息，银诺医药依苏帕格鲁肽α(怡诺轻)正式纳入“齐鲁保”互联网门诊特定药品清单，用于成人2型糖尿病患者治疗。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1424369.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","VXUS","BK4588","BK4585","02591"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1190139755","title":"异动解读 | 银诺医药-B盘中大涨5.74%，年报亮眼、减重管线进展及核心竞争力突出引价值重估","url":"https://stock-news.laohu8.com/highlight/detail?id=1190139755","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1190139755?lang=zh_cn&edition=full","pubTime":"2026-03-24 13:26","pubTimestamp":1774330005,"startTime":"0","endTime":"0","summary":"银诺医药-B（02591）今日盘中股价大幅上涨5.74%，引发市场关注。消息面上，公司此前发布的2025年年报表现亮眼，核心产品依苏帕格鲁肽α上市首年即展现强大商业化能力，毛利率高达89%，且公司财务状况稳健，现金储备充足。更关键的是，其减重适应症国内III期临床已完成全部患者入组，预计明年获批，市场潜力巨大，被视为公司未来业绩的“十倍级”增长引擎。此外，产品具备超长效给药、单靶点比肩双靶点疗效、以及全球唯一的“减脂保肌”临床数据等三大核心竞争力，构建了显著的差异化壁垒。这些积极因素共同强化了市场对公司从生物科技公司向成长型企业转型的预期，推动了投资者信心的提升和股价的走强。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02591"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154228635","title":"异动解读 | 银诺医药-B盘中大跌5.79%，年度亏损大幅扩大引发市场担忧","url":"https://stock-news.laohu8.com/highlight/detail?id=1154228635","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1154228635?lang=zh_cn&edition=full","pubTime":"2026-03-24 09:42","pubTimestamp":1774316545,"startTime":"0","endTime":"0","summary":"银诺医药-B(02591)今日盘中股价大跌5.79%，引起了投资者的广泛关注。消息面上，公司于近期发布了截至2025年12月31日止年度的业绩报告。报告显示，公司期内收入约为1.315亿元人民币，但净亏损高达3.41亿元，同比大幅扩大95.4%，每股基本亏损0.79元，且公司宣布不派发股息。这份业绩报告显示公司亏损额显著增加，远超市场预期，这直接打击了投资者信心，导致股价在交易时段承压下行。市场分析认为，亏损的急剧扩大反映了公司当前面临的经营挑战，引发了投资者对其未来盈利能力的担忧。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02591"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621575707","title":"银诺医药-B(02591)发布2025年度业绩，净亏损3.41亿元，同比扩大95.4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2621575707","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621575707?lang=zh_cn&edition=full","pubTime":"2026-03-23 23:10","pubTimestamp":1774278609,"startTime":"0","endTime":"0","summary":"智通财经APP讯，银诺医药-B(02591)发布截至2025年12月31日止年度业绩，集团产生约1.315亿元(人民币，下同)的收入，主要来自于在中国销售依苏帕格鲁肽α。净亏损3.41亿元，同比扩大95.4%;每股基本亏损0.79元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1417714.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"银诺医药-B(02591)发布2025年度业绩，净亏损3.41亿元，同比扩大95.4%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02591"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.innogenpharm.com","stockEarnings":[{"period":"1week","weight":-0.0597},{"period":"1month","weight":-0.2873},{"period":"3month","weight":-0.4816},{"period":"6month","weight":-0.5456},{"period":"1year","weight":-0.2323},{"period":"ytd","weight":-0.532}],"compareEarnings":[{"period":"1week","weight":-0.0209},{"period":"1month","weight":-0.0139},{"period":"3month","weight":-0.034},{"period":"6month","weight":-0.0015},{"period":"1year","weight":0.1057},{"period":"ytd","weight":0.0065}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"广州银诺医药集团股份有限公司是一家主要从事医药产品的研发及商业化的中国投资控股公司。该公司主要从事商业化原研人源长效胰高血糖素样肽-1（GLP-1）受体激动剂。该公司致力于开发糖尿病和其他代谢性疾病的疗法。该公司的主要产品依苏帕格鲁肽α（商品名：怡诺轻）用于治疗2型糖尿病（T2D）。该公司的主要候选药物管线产品包括YN014、YN401、YN209、YN203和YN202。该公司主要在国内市场经营其业务。","exchange":"SEHK","name":"银诺医药-B","nameEN":"INNOGEN-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"银诺医药-B(02591)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供银诺医药-B(02591)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"银诺医药-B,02591,银诺医药-B股票,银诺医药-B股票老虎,银诺医药-B股票老虎国际,银诺医药-B行情,银诺医药-B股票行情,银诺医药-B股价,银诺医药-B股市,银诺医药-B股票价格,银诺医药-B股票交易,银诺医药-B股票购买,银诺医药-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"银诺医药-B(02591)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供银诺医药-B(02591)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}